Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.60 USD
0.00 (0.00%)
Updated May 6, 2024 04:00 PM ET
After-Market: $64.58 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Alpine Immune Sciences, Inc. [ALPN]
Reports for Purchase
Showing records 81 - 100 ( 153 total )
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Nice View on the Horizon for Long-Term Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Q3 Financials; ALPN-303 Ph 1 Set to Initiate; Clinical Updates Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
3Q21 Results; ALPN-303 Steps Into the Spotlight;
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
More Data, More Confidence; ALPN-303 Appears Ready to Enter the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Financing Sets up Potential Expansion of Development Plans
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Q2 Financials; ALPN-101 SLE Study Underway; ALPN-202 ASCO Presentation Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
2Q21 Results; Pipeline Picks Up Steam With Three Programs at the Helm
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
NEON-2 Scores a Clinical Collaborator in Merck; Patient Dosing Begins
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Synergy Trial Gets Going with ALPN-101; Nice Check Cashed from Partner AbbVie
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
ALPN-202''s Future Appears Luminous with First Look at NEON-1
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Evidence Builds for ALPN-303s Differentiated Profile in B Cell Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D